Refractive Surgery: Phakic IOL's are the best option US and Global Experience


Richard A. Erdey, MD

RAE disclaimer

- 1998 Investigator ICL Myopia US FDA study
- 20 yrs experience with the ICL.
- 1990 Investigator Visx PRK FDA study

No financial interest in any products discussed






APPROVED - US FDA ICL MYOPIA - Dec 2005

- -3 to -15D "Correction of Myopia"
- -16 to -20.0 D "Reduction of Myopia" (in higher ranges ICL is not able to correct entire refractive disorder)
- 21 to 45 yrs age with stable myopia

Staar Toric ICL 1 to 4 diopters cylinder not available in US



Visian ICL - 2018

- Over 775,000 ICL's implanted worldwide
- > 99% satisfaction

Strong Points....

- .

- reversibility removability predictability stability quality of vision optical zone size cornea and crystalline lens remain untouched . predictable calculations and high quality of vision for future premium IOL implantations

Points of Criticism....


- endophthalmitis
- sizing
 cataract
 IOP



Endophthalmitis

- 0.0167% of cases (#17954)
- 3 reports, 2 with follow-up and full recovery .
- Staf. Epidermidis : no vision loss






Visian ICL sizes


- 12.1 mm
- 12.6 mm
- 13.2 mm
- 13.7 mm

FDA: ICL Size Determination

- · White to White measurement critical
 - use caliper
 - recline patient under microscope



FDA Nomogram: Initial Oversizing



Meta-analysis and review : effectiveness, safety, and central port design

of the intraocular collamer lens M. Packer, Clinical Ophthalmology 2016:10 1059-1077

OPTH-111620-meta-analysis-and-review---effectiveness--safety-an... 🔥


Study	N (eyes)	Length of follow-up	ICL removal, replacement, reposition % (N eyes)	ASC opacities % (N eyes)	Cataract surgery % (N eyes)	Pupillary block % (N eyes)	Ocular hypertension or glaucoma % (N eyes)
Seo et al ^{ie}	16	19.75±17.14 months (range: 4-56 months)	NR	NR	0	NR	NR
Kojima et al ¹¹	36	1 year	0	0	0	0	0
Alfonso et al ¹¹	188	5 years	0	1.1 (2)	0.5 (1)	0	0
Sheng et al ¹⁺	54	8.6±4.6 months (range: 3-20 months)	3.7 (2)	0	0	0	0
Kojima et al ^{te}	81	3 months	0	0	0	0	0
Reinstein et al ¹⁷	50	6.5±0.7 years (range: 4.1-7.4 years)	0	4.0 (2)	0	0	NR
Alfonso et al ^{mi}	138	6 months	0	0	0	0	0
Higueras- Esteban et all"	35	3 months	NR	NR	NR	0	0
Cao et al ¹¹	62	3 months	0	NR	0	0	0
Alfonso et al ^m	35	I year	0	0	0	0	0
Gomez-Bastar et al ¹⁴	349	47±31 months (range: 3-127 months)	1.2 (4)	0	0	0	0
Kamiya et al ^{//}	46	I year	0	0	0	0	0
Lisa et al ⁴	121	1 year	0	0	0	0	0
Lisa et al ²¹	147	1 year	0	0	0	0	0
Malyogin et all ¹¹	29	1 year	0	0	0	0	0
Total N	1.387		0.4 (6)	0.3 (4)	0.1 (1)	0	0








METHODS: This prospective molecular clinical study evaluated eyes having pICN, (Visiae inspiratable Collamer Level) and entricipacities durat analysis was applicated and clinical input from investigators area from properties auto-coll to shuture (BT3) of postparative suita. The regression data and clinical input from investigators area than used to develop a pICN, string nom nonrogens used only BT3 and pICN, power as visited to determine levely. Investigators stud; (H2) pin) and exercisive as profile and only BT3 and pICN, power as visited to determine levely. Investigators was studied progress (Omplied and H2 assign methods) used in the Unided Statis that are based in which south (VITV) measurements. **RESULTS:** One area was excluded from the analysis because the arrong largely pICN, was placed (12 amin instead of norm recommended 12 and in, methods). The manap patient based on which south (VITV) measurements. (Darling 810 b 552 uni), there are no classe of instead on the manap patient of the manap patient and the manap of the manap and the progress (Darling 810 b 552 uni). There are patiented in difference and pICN to 155 to 610 v. Classes as 330 units methods and on the classes are not classe of instead on the stude of the manap patient methods and VITV measurements and have an exclude in difference and pICN to 150 to 610 v. Classes as 150 v. The terms are not classe of instead on the stude on the manap developed in UIM nonequers. Based on the stude of the terms and the stude of the manap and the stude of the terms of the Still 50 to 610 v. Classes as 150 v. The terms area to classe of instead on the stude of the terms of the Still 50 to 610 v. Classes as 150 v. The terms area to classe of instead on the stude of the terms of the Still 50 to 610 v. Classes and 150 v. The terms area to classe of the terms of the stude of the terms of the still terms of terms of the still stude of terms of the stude of the terms of the still stude of terms of terms of the stude of terms of the stude of terms of




New Nomogram						
ent STS Nomogram	My Current Nomogram					
	STS:					
ise 12.1	≤10.8 use 12.1					
12.2 use 12.6	10.8 to 11.7 use 12.6					
12.9 use 13.2	11.8 to 12.9 use 13.2					
ise 13.7	>13.0 use 13.7					
er of ICL is -3 to -7.5, er at threshold; if -8 to -16, go smaller shold	If Lens Rise <650 or >900, go to respective larger/smaller size when within 0.2 of the STS threshold***					
	*Account For Special Anatomy					



ICL Complications

Cataract Incidence US FDA study: 1.7% after 7 yrs All eyes that developed cataracts > -12D

ICL Complications Anterior Subcapsular Cataract



POST-OPERATIVE FOLLOW UP

Reviewed on day 1 & 7, 6 weeks Thorough ocular examination Check Manifest refractive error

ESSMENT OF VAU

Curre

STS

<11.0 u 11.1 to


12.3 to

>13.0 u

If powe go large

power at three

Central distance between anterior surface of the crystalline lens and posterior surface of the ICL Ideal sized ICL will provide a vault of 0.250 to 0.750 mm (% CT to 1 % CT)




Safety Evolution Data combined with Dr. Alfonso

	¥4		Vec	
N	2456	1976	1888	
Cases of Cataract	21	4		
% of cases with cataracts	1.00 N	0.01 %	•	
Years of follow-up	Up to 14 y	Up to 6 y	Up to 4 y	_
			Med	
			Mes	


Literature Review V4c Visian ICL

		1		3			
Pinterne		Norma	Contract	Pagement Dispaced	Page Street	- 144	
Shimizu, Br J Ophthalmology 2012 Mar	6 months	20	0	0	0		
Alfonso, J Cataract Refract Surg 2013 Jun	6 months	138	0	0	0	0	
Gonzalez-Lopez, J Cataract Refract Surg 2013 Dec	I month	100			0	0	
Kamiya, J Cataract Refract Surg 2015 Jan	I year	23	0	0	0	0	
Alfonso, J Cataract Refract Surg 2015 Apr	6 months	781	0				
Lisa, J Cataract Refract Surg 2015 Jun	1 year	147	0	0	0	0	
Fernandez-Vigo, AJO 2016	3 months	50	0		0	0	
Shimizu, Medicine 2016 Apr	5 years	32	0	0	0	0	Medipoli
Total		1291	1				




Yag Peripheral Iridotomy . Surgical Iridectomy





• 0.360mm central hole - no iridotomy required




Strong Points....

- reversibility removability predictability stability quality of vision optical zone size cornea and crystalline lens remain untouched predictable calculations and high quality of vision . for future premium IOL implantations




The Visian Myopic Implantable Collamer Lens Does Not Signific Affect Axial Length Measurement the IOLMaster



Better IOL calculations


No changes in corneal quality








1469 EVO implants 306 with F-U > 4 years

Parameter	Meens SU (runger			
Age (years)	31.8 1 7.6	(19 to 45)		
Sphere (D)	.5.97+2.82	(0.75 to .14.75)		
Cylinder (D)	0.94±0.87	(0 to -4.25)		
ACD (mm)	324±0.20	(280 to 371)		
WTW (run)	11.93±0.96	(11.00 to 12.70)		
Scotopic Pupil (mm)	6.30±0.66	(4.5 to 7.75)		
ECC (ottion?)	9421 <u>24</u> 271 3	2 (2235 to 2690)		
ICP (nnHg)	13.84±3.38	(8 to 22)	6	
			Medipolis	














Cornea and crystalline lens remain untouched


- Related issues only for LVC
 - Dry eye
 - Ectasia
 - IOL calculation
 - · HOA and premium IOL implantation

Medipolis













US FDA ICL MYOPIA SAFETY – Cornea Endothelial cell loss


- Consistent with expected loss associated with all intraocular procedures
- Initial acceptable very small loss 0.6% with subsequent remodeling
- Endothelial cell cts stable long term.
- Consistent with healthy, stable cornea endothelium












Keratoconus – Dalk - ICL

- DALK: -6.50 + 1.25 x 150 20/40
- ICL : UCVA 20/25

Indications every eye suitable for ICL unless there is a contra-indication LASIK and dry eye = dramatic



Visian ICL

- my favorite operation to perform based on the outstanding results.
- It is the best vision correction procedure I have ever seen.
- Once you chose ICL surgery for your patients, you can look forward to your patients having the best vision that there is.

It will truly change the way your patients see the world!

Toric, Aquaport, EVO+ available internationally

ICL vs LASIK - Patient Selection

- 25 yo 2.50 OU
- 48 yo 2.50 OU

ICL vs LASIK – Patient Selection

- 25 yo 4.00 OU
- 48 yo 4.00 OU

ICL vs LASIK - Patient Selection

- 25 yo -6.00 OU
- 48 yo -6.00 OU

ICL vs LASIK - Patient Selection

- 25 yo 7.50 OU
- 45 yo 7.50 OU


ICL - Case #1

30 yo female

OD -3.75 + 0.25 x 100 20/20 OS - 3.75 + 0.25 x 127 20/20

ICL OU same day sequential

UCVA OD 20/15-OS 20/15-OU 20/15



ICL - Case #3

25 yo female


OD -10.5 + 1.25 x 32 20/20 OS - 11.0 + 0.75 x 169 20/20

ICL OD OS one wk apart

UCVA 3 mo post-op OD 20/15-3 OS 20/15-3 OU 20/15-1

ICL + LASIK


- -25.0 D OU 20/50
- ICL OU
- post op 6.50 OU 20/30!!
- LASIK ?



- keratoconus after ICL combined with clear cornea incisionUCVA: 20/20
- Vs. Pre-op BSCVA 20/30

Mild Keratoconus / Myopia

- Pre-op: -12.50 + 4.50 x 65 20/40
- Post -ICL -0.75 + 0.75 x 90 20/25



-7.50 + 3.00 x 90 OU

- K's 40 OU
- LASIK?
- ICL + LASIK?
- Toric ICL EVO+?

Visian ICL

my favorite operation to perform based on the outstanding results.

It is the best vision correction procedure I have ever seen

Once you chose ICL surgery for your patients, you can look forward to your patients having the best vision that there is.

It will truly change the way your patients see the world!

oric, Aquaport, EVO+ available internationall



